-
England bowl against Pakistan in first Test of post-Bazball era
-
ICC says US sanctions 'flagrant attack' on court independence
-
Villa sign Japanese 'keeper Suzuki, Italian defender Ruggeri
-
Kyrgios admits 'huge mistake' after failing test for cocaine
-
Injury-plagued Pogba released by Monaco
-
Europe can't afford to miss AI revolution: ECB chief
-
Japanese 'keeper Suzuki signs for Aston Villa
-
Suthar shines as India crush Sri Lanka in 600th Test
-
Paul Pogba to be released by Monaco: club
-
UK PM unveils plan to help rough sleepers off streets by Christmas
-
Texas Counseling Center Highlights the Role of Counseling in Supporting Immigration Psychological Evaluations
-
Tokyo opposes US sanctions on Japanese ICC chief Akane
-
Pakistan govt to challenge court on moving ex-PM Khan to private hospital
-
Humanoid-maker Unitree surges more than 600% on Shanghai debut
-
India four wickets away from victory in Sri Lanka Test
-
Bowling great Donald warns Bangladesh that Australia will hit back hard
-
Belgian wildfire 'encircled' but situation still 'complicated'
-
STARPRIME Completes Beta Testing of Market-Maker Model for Retail Brokers
-
Southern African mothers plead for sons lured to Russia's war
-
Campaigns kick off in Nigerian presidential race
-
Palestinian-American hoists US flag on home besieged by settlers
-
Aussie Rules club suspends five players for drinking, bringing women to hotel
-
Freedom Holding Marks New Türkiye Milestone as Freedom Yatırım Secures Brokerage License
-
Trump pauses 50% tariffs on Canadian goods for three days
-
Humanoid resources: China's robots search for workforce breakthrough
-
Five Premier League stars to watch this season
-
China goes rural with data centres in quest to power AI
-
China's robots open to opportunities in search of commercial breakthrough
-
Trump pauses planned 50% tariffs on Canadian goods for three days
-
Tech leads losses as Asian stocks track Wall St selloff
-
Ikitau, Suaalii named in Australia squad for Argentina Tests
-
US, South Korea cut drills short after Trump criticism
-
'American Doctor' shows brutality of conflict in Gaza
-
Italian scientists bet on octopus to fight crab invasion
-
New Zealand blocks lawsuits against firms over climate harm
-
New 'Insidious' reflects anxiety of being a new parent: director
-
Aussie Rules club suspends five players amid police probe
-
No.1 Sabalenka slams Wang to advance at Cincinnati
-
No.1 Sabalenka slams Wang to power ahead in Cincinnati
-
Turkey rejects Israeli claims after strike on Syria air base
-
Israel blames Turkey after strike on Syria air base
-
Who is the Best Facial Feminization Surgeon in the World?
-
Who Does the Best Male Facelift Surgery in Sarasota?
-
Bioz and InvivoGen Elevate Scientific Discovery with an Expanded Digital Research Experience
-
BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
-
Empire Metals Limited Announces MRE Upgrade at Pitfield Titanium Project
-
Elevate Acquires Lupl
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - August 19
-
Caldwell Strengthens Life Sciences and Healthcare Practice with Addition of Olga Kozlova in Dubai
-
Best Place to Buy Gold IRA in 2026 (Guide Released)
Trump signs order to fast-track research on psychedelic drugs
US President Donald Trump on Saturday announced an easing of restrictions on research into psychedelic drugs -- such as so-called "magic mushrooms" -- that have shown promise in treating people with mental health conditions.
Flanked by US Health Secretary Robert F. Kennedy Jr, top medical officials and podcaster Joe Rogan, who has pushed for access to the drugs, Trump signed an executive order that would help federal researchers cut through the red tape to allow for quicker studies.
The president said the order would "clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA (Food and Drug Administration) and the Department of Veterans Affairs and facilitate fast rescheduling of any psychedelic drugs that become FDA approved."
Currently, many psychedelics including LSD and psilocybin ("magic mushrooms") are classified -- or "scheduled" -- as having high abuse and addiction potential, and are not approved for medical use, limiting the ability for scientists to study them.
If the FDA, which is charged with regulating pharmaceuticals in the United States, officially finds a medical benefit for some of the psychedelics, they could be rescheduled, allowing for greater clinical use.
The order only provides for accelerated research and does not immediately require law enforcement authorities to reclassify the drugs, meaning therapeutic use will not expand immediately.
In recent years, there has been a growing push to research the effects of the drugs in treating people -- especially war veterans -- with difficult anxiety and depression cases, especially those who had experienced traumatic stress.
Many veterans and other patients have complained that traditional antidepressant cocktails not only fail to work but change their personalities in ways that alienate them from their friends and family.
In 2023, 6,398 veterans took their own lives, the Department of Veterans Affairs said.
During the signing ceremony at the White House, Trump pointed to one drug called ibogaine, claiming patients who had taken it "experienced an 80 to 90 percent reduction in symptoms of depression and anxiety within one month."
"Can I have some, please?" he joked.
The full extent of the benefits and potential side effects of psychedelic medications is not yet known, since research has been restricted.
While many are thought to show promising mental health benefits, there are risks. Ibogaine, for instance, is thought to potentially damage the heart.
If you are a US veteran in need of help, or concerned about one, you can dial 988 and press 1, or visit www.veteranscrisisline.net.
P.M.Smith--AMWN